STOML2 and neoplasm: Studies on clinical application of sorafenib in CRC patients have been conducted in recent decades [51, 52], and our findings have validated that sorafenib attenuates STOML2-induced CRC proliferation and tumor growth, with antagonizing effect to MAPK pathway (Fig. 6A), which may provide evidence for potential use of sorafenib in decreasing tumor burden of CRC.